Cover Image
市場調查報告書

Saphris(精神分裂症):市場預測與分析

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 299173
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
Saphris(精神分裂症):市場預測與分析 Saphris (Schizophrenia) - Forecast and Market Analysis to 2022
出版日期: 2014年02月28日 內容資訊: 英文 44 Pages
簡介

Saphris是dibenzazepine精神隔斷藥的一種,在歐盟區內以「Sycrest」之名推出。這個醫藥品具有親脂性特徵,活用以三環系、異環式dibenzazepine為基礎結構這樣的特質,可以較小的阻力穿過血腦障壁。由於和Abilify不同,Saphris如同多巴胺D2受體的拮抗劑般起作用,可有效針對精神分裂症的陽性症狀,但同時長期使用引發錐體外症的可能性也會升高。

本報告提供精神分裂症治療藥之一──Saphris 的全球市場相關分析,提供精神分裂症概要和治療方法,Saphris 商品資訊(特色·功效·安全性等)和競爭力,競爭的企業·藥品概要,全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 分析概要
  • 相關分析
  • 預定發行的相關分析

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理
  • 症狀

第4章 疾病的管理

  • 診斷
    • 主觀的評估
    • 疾病的分類
  • 治療方法概要
    • 治療精神分裂症相關的急性激越症狀
    • 精神分裂症的維持療法

第5章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估

第6章 關於Saphris(asenapine maleate)

  • 概要
  • 急性治療藥的功效
  • 維持治療藥的功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表一覽

目錄
Product Code: GDHC356DFR

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Saphris (asenapine maleate), also known as Sycrest in the EU, is a dibenzazepine neuroleptic. The drug utilizes the tricyclic dibenzazepine heterocycle as a basic structural feature which is lipophilic in its nature, allowing Saphris to cross the blood-brain barrier with less resistance. Unlike Abilify, Saphris acts as an antagonist at dopamine D2 receptors, meaning that Saphris can effectively target positive psychotic symptoms associated with schizophrenia; however, it has a higher chance of causing extrapyramidal symptoms over the long term.

Scope

  • Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Saphris including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Saphris for the top six countries from 2012 to 2022.
  • Sales information covered for the US, Germany, Italy, Spain, the UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Saphris performance
  • Obtain sales forecast for Saphris from 2012-2022 in the top six countries (the US, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
    • 4.1.1. Subjective Assessments
    • 4.1.2. Disease Subtypes
  • 4.2. Treatment Overview
    • 4.2.1. Treatment of Acute Agitation Associated with Schizophrenia
    • 4.2.2. Maintenance Treatment of Schizophrenia

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Saphris (asenapine maleate)

  • 6.1. Overview
  • 6.2. Efficacy as an Acute Treatment
  • 6.3. Efficacy as a Maintenance Treatment
  • 6.4. Safety
  • 6.5. SWOT Analysis
  • 6.6. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosis and Treatment Rates
    • 7.4.2. Adherence Rates
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Key Opinion Leaders
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Reviewers
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptom Clusters of Schizophrenia
  • Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis
  • Table 3: Development-Based Classification of Antipsychotic Drugs
  • Table 4: Receptor Binding Profiles of Atypical Antipsychotics
  • Table 5: Guidelines for the Treatment of Schizophrenia
  • Table 6: Leading Branded Treatments for Schizophrenia, 2013
  • Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014
  • Table 8: Product Profile - Saphris
  • Table 9: Saphris SWOT Analysis, 2013
  • Table 10: Global Sales Forecast ($m) for Saphris, 2012-2022
Back to Top